Jove
Visualize
Contact Us

Related Experiment Videos

Update on photodynamic therapy.

Jennifer Landy1, Gary C Brown

  • 1Department of Ophthalmology, University of South Florida, Florida, USA.

Current Opinion in Ophthalmology
|June 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.

Ophthalmology. Retina·2023
Same author

Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost-Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration.

Ophthalmology and therapy·2023
Same author

Preference-based comparison of quality of life associated with vision loss in Black and White ophthalmic populations in the US.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2022
Same author

Quality of life associated with no light perception vision.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2022
Same author

Re: Le et al.: Associations between age-related eye diseases and Charles Bonnet Syndrome in participants of the Age-Related Eye Disease Study 2: Report Number 26 (Ophthalmology. 2022;129:233-235).

Ophthalmology·2022
Same author

Value-based Medicine and Gene Therapy.

International ophthalmology clinics·2021
Same journal

Laser vision correction (LASIK, PRK, SMILE) with simultaneous accelerated corneal crosslinking.

Current opinion in ophthalmology·2026
Same journal

Traumatic macular hole: observe, operate, or other options.

Current opinion in ophthalmology·2026
Same journal

The evolving role of artificial intelligence in ophthalmology: basic science, translation, and clinical integration.

Current opinion in ophthalmology·2026
Same journal

Editorial: reducing risk for refractive surgery.

Current opinion in ophthalmology·2026
Same journal

Updates on Refractive Surgery: Benefits, Risks, and Costs of Modern Treatment Options.

Current opinion in ophthalmology·2026
Same journal

Corneal Allogeneic Intrastromal Ring Segments for keratoconus - recent evidence and the move to customized and custom shaped CAIRS.

Current opinion in ophthalmology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Photodynamic therapy with verteporfin benefits specific forms of age-related macular degeneration and high myopia. Further research is needed for other conditions like angioid streaks and idiopathic choroidal neovascularization.

Area of Science:

  • Ophthalmology
  • Medical Therapy

Background:

  • Photodynamic therapy (PDT) with verteporfin is an established treatment for certain vision-threatening conditions.
  • Age-related macular degeneration (AMD) and high myopia can lead to choroidal neovascularization (CNV), impacting central vision.

Purpose of the Study:

  • To review the current efficacy of photodynamic therapy with verteporfin for various causes of choroidal neovascularization.
  • To identify patient populations that benefit from this treatment and those requiring further investigation.

Main Methods:

  • Review of existing clinical data and FDA approvals for verteporfin in treating CNV.
  • Analysis of treatment outcomes in patients with different types of CNV, including age-related macular degeneration, high myopia, and other less common causes.

Related Experiment Videos

Main Results:

  • Verteporfin PDT is effective for subfoveal, predominantly classic CNV in AMD.
  • The therapy is also beneficial for subfoveal lesions secondary to high myopia.
  • Efficacy is not established for minimally classic CNV, occult CNV (pending FDA review), angioid streaks, ocular histoplasmosis, or idiopathic CNV.

Conclusions:

  • Photodynamic therapy with verteporfin offers significant benefits for specific subtypes of choroidal neovascularization.
  • Randomized clinical trials are necessary to establish efficacy for less common etiologies of CNV.
  • Further data is required for FDA approval in cases of occult subfoveal CNV.